TWST icon

Twist Bioscience

45.16 USD
-1.04
2.25%
Updated Feb 12, 11:49 AM EST
1 day
-2.25%
5 days
-16.37%
1 month
3.63%
3 months
-0.22%
6 months
5.74%
Year to date
-0.33%
1 year
11.20%
5 years
45.96%
10 years
222.57%
 

About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Employees: 923

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

193% more call options, than puts

Call options by funds: $5.94M | Put options by funds: $2.02M

17% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 77

3.67% less ownership

Funds ownership: 120.36% [Q2] → 116.69% (-3.67%) [Q3]

7% less funds holding

Funds holding: 261 [Q2] → 242 (-19) [Q3]

11% less capital invested

Capital invested by funds: $3.45B [Q2] → $3.09B (-$363M) [Q3]

32% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 50

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$40
11%
downside
Avg. target
$54
20%
upside
High target
$62
37%
upside

6 analyst ratings

positive
83%
neutral
0%
negative
17%
Scotiabank
Sung Ji Nam
43% 1-year accuracy
9 / 21 met price target
37%upside
$62
Sector Outperform
Maintained
4 Feb 2025
JP Morgan
Rachel Vatnsdal
61% 1-year accuracy
11 / 18 met price target
11%downside
$40
Underweight
Maintained
4 Feb 2025
Baird
Catherine Ramsey
85% 1-year accuracy
11 / 13 met price target
20%upside
$54
Outperform
Maintained
4 Feb 2025
Wolfe Research
Doug Schenkel
40% 1-year accuracy
2 / 5 met price target
33%upside
$60
Outperform
Initiated
13 Dec 2024
TD Cowen
Steven Mah
80% 1-year accuracy
4 / 5 met price target
28%upside
$58
Buy
Reiterated
26 Nov 2024

Financial journalist opinion

Based on 8 articles about TWST published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Neutral
Finbold
6 days ago
Cathie Wood dumped Palantir to buy these biotech stocks
Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.
Cathie Wood dumped Palantir to buy these biotech stocks
Negative
Seeking Alpha
6 days ago
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Twist Bioscience: Valuation Is Weighing On The Stock
Neutral
Seeking Alpha
1 week ago
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by.
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 week ago
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 week ago
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced financial results and business highlights for the first quarter fiscal 2025 ended December 31, 2024. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal first quarter 2025 earnings report.
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
Neutral
GlobeNewsWire
2 weeks ago
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033). The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% during the forecast period (2025-2033).
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
Neutral
Business Wire
3 weeks ago
Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, before the opening of the market on February 3, 2025. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financia.
Twist Bioscience to Report Fiscal 2025 First Quarter Financial Results on Monday, February 3, 2025
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
Positive
Zacks Investment Research
1 month ago
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
Charts implemented using Lightweight Charts™